A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

This is an early-phase study testing a new drug called RNK08954 in people with advanced or metastatic solid tumors that have a specific genetic mutation called KRAS G12D. This mutation is found in several cancers including pancreatic, colon, and lung cancer. The study aims to find the safest and most effective dose. **You may be eligible if...** - You are 18 or older - Your tumor has been confirmed to have the KRAS G12D mutation (detected by genetic testing) - You have already tried standard treatments that are no longer working - You have measurable tumors on scans - You are in good health (ECOG 0–1) and have adequate organ function - You can swallow pills **You may NOT be eligible if...** - Your tumor tissue sample is not available for testing - Your blood counts or organ function are outside acceptable ranges - You have unresolved serious side effects from prior cancer treatment Talk to your doctor to see if this trial is right for you.